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Abstract
Background: Whole-exome sequencing using next-generation technologies has been previously demonstrated to
be able to detect rare disease-causing variants. Progressive external ophthalmoplegia (PEO) is an inherited
mitochondrial disease that follows either autosomal dominant or recessive forms of inheritance (adPEO or arPEO).
AdPEO is a genetically heterogeneous disease and several genes, including POLG1 and C10orf2/Twinkle, have been
identified as responsible genes. On the other hand, POLG1 was the only established gene causing arPEO with
mitochondrial DNA deletions. We previously reported a case of PEO with unidentified genetic etiology. The patient
was born of a first-cousin marriage. Therefore, the recessive form of inheritance was suspected.
Results: To identify the disease-causing variant in this patient, we subjected the patient’s DNA to whole-exome
sequencing and narrowed down the candidate variants using public data and runs of homozygosity analysis.
A total of 35 novel, putatively functional variants were detected in the homozygous segments. When we sorted
these variants by the conservation score, a novel missense variant in RRM2B, whose heterozygous rare variant had
been known to cause adPEO, was ranked at the top. The list of novel, putatively functional variants did not contain
any other variant in genes encoding mitochondrial proteins registered in MitoCarta.
Conclusions: Exome sequencing efficiently and effectively identified a novel, homozygous missense variant in
RRM2B, which was strongly suggested to be causative for arPEO. The findings in this study indicate arPEO to be a
genetically heterogeneous disorder, as is the case for adPEO.
Background
Massively parallel sequencing, also known as next gen-
eration-sequencing, is a revolutionary technology that
enables us to obtain large amounts of genomic sequence
information in an incomparably more rapid and less
expensive manner than before [1]. This technology is
applicable for various investigations, including resequen-
cing of full genomes or more targeted parts thereof for
discovery of genomic variations, genome-wide mapping
of structural rearrangements, transcriptome sequencing,
genome-wide epigenetic analysis, metagenomic sequen-
cing, and so on [2]. Whole-genome and whole-exome
(sequences of all protein-coding regions) resequencing
aiming at identification of causative variants for rare,
inherited diseases is one of these applications, and have
demonstrated their efficiency and effectiveness (reviewed
in [3]).
Previously, we reported a patient who had been born of
a first-cousin marriage and was suspected to be affected
by inherited progressive external ophthalmoplegia (PEO)
[4]. Inherited PEO is a form of mitochondrial disease that
follows either autosomal dominant or recessive forms of
inheritance (adPEO (MIM 157640; 609283; 609286;
610131, 613077) or arPEO (MIM 258450)). The charac-
teristic findings of inherited PEOs are multiple mito-
chondrial DNA (mtDNA) deletions and ragged red fibers
in the muscle biopsy [5]. Typical clinical symptoms are
bilateral ptosis and paralysis of the extraocular muscle.
Other symptoms include exercise intolerance, cataracts,
hearing loss, sensory axonal neuropathy, optic atrophy,
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[6-10].
In the present case, the recessive form of inheritance
was suspected because of the patient’s family history.
However, no pathogenic variant in POLG1 (MIM 174763),
which encodes a mitochondrial DNA polymerase and was
t h eo n l ye s t a b l i s h e dg e n ew h o s ev a r i a n t sw e r ek n o w nt o
cause arPEO so far, was identified [4].
T h ep r o b a n di nt h i ss t u d yw a st h eo n l yc h i l da n dt h e
available genetic information from family members was
limited. Therefore, it was almost impossible to identify the
causative variant using linkage analysis. On the other
hand, exome sequencing using a next-generation sequen-
cer has demonstrated its utility to detect causative variants
of rare disease using a small number of samples, especially
in the case of consanguineous family. Here, we performed
exome sequencing in combination with runs of homozyg-
osity (ROH) analysis in order to identify the causative
variant in this patient.
Results
Exome sequencing identifies a novel, homozygous
missense variant in RRM2B
A total of 3.2 Gb of sequence was generated from one lane
of sequencing using the Illumina Genome Analyzer II
(Illumina, San Diego, CA, USA). The proportion of the
targeted exome covered at 1×, 5× and 10× was 96.3%,
88.0% and 78.3%, respectively. The mean coverage was
37.2×. A total of 19, 215 variants were detected in the cod-
ing regions defined by RefSeq Gene [11] and their flanking
splice sites. The number of detected coding variants does
not deviated greatly from that in previous reports [3,12].
After removing variants registered on the public database
of sequence variants (dbSNP, build 130) or found in eight
exomes of HapMap individuals [12] or the exome of a sin-
gle, healthy, unrelated Japanese individual, which was ana-
lyzed in the same run of Illumina Genome Analyzer II
sequencing, 1, 336 variants remained. Among these, 592
variants, including 141 homozygous ones, were functional
(nonsense, missense, frameshift or splice site). Next, we
performed ROH analysis to narrow down the candidate
regions, using the base calling data on single nucleotide
variants in this patient. To enhance the accuracy of the
variant calling used for this analysis, 1) only the data of
single nucleotide variants were used and insertion/deletion
variants were excluded because of lower reliability of the
detection of insertion/deletion variants [13], 2) variants
called with coverage less than 8× were excluded, 3) var-
iants called with a coverage of more than 100× were
excluded because genomic regions that are known to be
duplicated or have similar sequences such as pseudogenes
tend to be read with high coverage. Because the primary
aim of this analysis was not to evaluate ROH segments
precisely, but to narrow down the list of candidate variants
without overlooking the causative variant, we used relaxed
criteria of ROH segments. The total size of ROH regions
was 992 Mb (about 32% of the genome), which was signifi-
cantly larger than the expected total size of ROH segments
in an offspring born from a first cousin marriage (one-
eighth of the genome). A total of 35 novel and functional
variants in 33 genes were identified in ROH segments. A
summary of the filtering strategy is given in Table 1.
When we sorted these listed variants by a conserva-
tion score (phyloP score) to identify those that were
most likely to be functional, a novel missense variant in
RRM2B (g.341G > A, p.P33S), whose rare, heterozygous
variant had been known to cause adPEO, was ranked at
the top (Table 2).
The existence of the RRM2B variant in the patient’s
DNA was confirmed by Sanger sequencing (Figure 1a). As
expected, each of the parents had this variant in the het-
erozygous state. This variant changes an amino acid resi-
due that is highly conserved across 44 vertebrates (Figure
1b). Among 359 control subjects (718 chromosomes) of
Japanese origin, one subject carried this variant in the het-
erozygous state.
Exclusion of other variants that could cause PEO
In the list of 35 novel and functional variants in the ROH
segments, no other variants in genes encoding mitochon-
drial proteins were registered in Human MitoCarta [14].
We could not find any pathogenic mutations in other
genes known to cause mitochondrial diseases with multi-
ple mtDNA deletions (POLG1, POLG2 (MIM 604983),
C10orf2 (MIM 606075), SLC25A4 (MIM 103220), OPA1
(MIM 605290), TYMP (MIM 131222) and WFS1 (MIM
606201)) in exome analysis, as was observed in a previous
study using Sanger sequencing [4]. Although the mtDNA
sequence was not targeted by the SureSelect Human All
Exon Kit (Agilent, Santa Clara, CA, USA), 16, 558 of 16,
568 (99.9%) bases in mtDNA were read four or more
times due to its higher copy number than nuclear DNA,
and no known pathogenic variant was found. Because of
the family history of the patient, we suspected that his
disease was caused by a recessive mutation. However,
there was another possibility that de novo variants affect
him in a dominant manner. To test this possibility, we
investigated whether he had de novo variants that could
explain his symptoms. In the list of 592 novel and puta-
tively functional variants, there were 26 heterozygous
variants in genes registered in MitoCarta. Among them,
five variants were not found in dbSNP132 or 1000 Gen-
ome Project data [15] (SNP calls released in June 2011),
and were located at conserved base positions (phyloP
score > 2). By performing Sanger sequencing, we con-
firmed that all of these variants were not de novo,b u t
inherited from either of his healthy parents or found as a
false positive (Table 3).
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The mtDNA copy number relative to nuclear DNA in
the patient’s skeletal muscle was not decreased, but
rather increased (Figure 2). As expected, the ND4/RNa-
seP ratio was lower than the ND1/RNaseP ratio in the
patient, which suggests increased levels of mtDNA dele-
tions that include the ND4 region, such as the 4, 977-bp
common mtDNA deletion [16]. This result indicated
that the clinical manifestation in the present patient was
not due to mtDNA depletion.
Discussion
In this study, we subjected DNA from a PEO patient with
unidentified genetic etiology to exome sequencing and
detected a novel, homozygous missense variant in
RRM2B. RRM2B encodes p53-inducible ribonucleotide
reductase small subunit 2-like protein (p53R2) and this
protein plays an essential role in the maintenance of
mtDNA by reducing ribonucleotides in the cytosol [17],
as is indicated by the fact that rare variants in this gene
cause various forms of mitochondrial diseases character-
ized by mtDNA depletion and deletions. To our knowl-
edge, 15 cases of mitochondrial depletion syndrome
(MIM 612075) from 11 families [18-22] and one sporadic
case of mitochondrial neurogastrointestinal encephalopa-
thy [23] (MIM 603041) associated with homozygous or
compound heterozygous rare variants in RRM2B have
been reported. More recently, two families with adPEO
due to a heterozygous nonsense variant were described
[24]. In the screening of RRM2B variants in 50 mitochon-
drial disease patients without causative variants in
POLG1 and C10orf2, one Kearns-Sayre syndrome (MIM
530000) patient who carried two different novel missense
variants and one PEO patient who carried an in-frame
deletion were identified [25].
The clinical symptoms and findings in the muscle
biopsy of our case were typical for Mendelian-inherited
PEO. No members of his maternal family have shown
any neuromuscular symptoms, suggesting that the
mtDNA deletions of the patient were not maternally
inherited. Real-time quantitative PCR analysis revealed
that there was no mtDNA depletion. We did not observe
gastrointestinal dysmotility, cardiac conduction abnorm-
alities, pancreatic dysfunction and sensory ataxic neuro-
pathy, which are characteristic symptoms for other
mitochondrial diseases associated with mtDNA deletions,
namely mitochondrial neurogastrointestinal encephalo-
pathy, Kearns-Sayre syndrome, Pearson syndrome, and
Table 1 Summary of the filtering to narrow down the candidates for the causal variant
Criteria for the filtering Number of remaining variants
Coding variants 19, 215
Not in dbSNP130 2, 015
Not in eight HapMap exomes [12] 1, 833
Not in in-house data of a healthy Japanese individual 1, 336
Functional (missense, nonsense, frameshift and splice site) 592
In run-of-homozygosity regions 35 (in 33 genes)
The filtering was performed using the listed criteria in descending order.
Table 2 List of novel and functional variants in run-of-homozygosity regions
Chromosome Position Reference allele Variant allele Variant calling/coverage Gene Amino acid change PhyloP score
8 103313660 G A 58/58 RRM2B Pro33Ser 6.741
1 39620317 G A 5/7* MACF1 Arg2523Gln; Arg3025Gln 5.329
4 107449465 A C 63/63 MGC16169 Asn34Lys 5.199
22 15980313 C T 5/5* LOC100287323 Val569Ile 4.997
11 64117795 G A 4/4* SLC22A12 Trp37Stp; Trp258Stp 4.945
10 29010439 G C 24/24 BAMBI Gly108Ala 4.878
20 49482400 G A 4/4* NFATC2 Ala778Val 4.437
1 238437608 C T 10/12 FMN2 Pro1101Leu 3.804
1 85362528 T - 65/69 WDR63 Splice site 3.503
3 99094433 A G 24/34 DKFZp667G2110 Lys546Glu 3.299
3 336547 T G 23/23 CHL1 Ser30Ala 3.014
3 46595758 C G 27/40* LRRC2 Arg41Gly 2.522
4 169335658 A C 9/13* ANXA10 Thr193Pro 2.257
5 140538797 C T 127/127 PCDHB8 Thr333Ile 2.011
Variants with PhyloP score > 2 are listed. Asterisks indicate variants with coverage < 8× or a variant calling/coverage ratio < 0.7; the reliability of these variant
calls is generally lower than that of the others.
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esis (MIM 607459), respectively. Therefore, this patient
was diagnosed as having arPEO caused by a homozygous
missense variant of RRM2B.
Before this study, POLG1 had been the only estab-
lished gene responsible for arPEO, while adPEO is a
genetically heterogeneous disease, caused by rare var-
iants in POLG1, POLG2, C10orf2, SLC25A4, OPA1 and
RRM2B. The results of this study identifying the second
responsible gene for arPEO indicate that arPEO is also a
genetically heterogeneous disease, as is the case for
adPEO.
The symptoms observed in this patient included major
depressive episodes. Frequent comorbidity of mood dis-
orders in patients of mitochondrial disease has been
generally recognized [26] and several lines of evidences
have supported the possible involvement of mitochon-
drial dysfunctions in the pathophysiology of mood
g.341G>A, p.P33S
(a)
(b)
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Figure 1 The identified disease-associated variant in RRM2B. (a) Partial sequence of RRM2B in the patient’s DNA (left) and control DNA
(right). Red squares indicate the base position of the g.341G > A, p.P33S variant. (b) The substituted amino acid residue (red box) is highly
conserved across 44 vertebrate species (from the UCSC genome browser [31]).
Table 3 List of novel, putatively functional and heterozygous variants in mitochondrial genes
Chromosome Position Reference
allele
Variant
allele
Variant calling/
coverage
Gene Amino acid
change
PhyloP
score
Inheritance
7 30615756 G C 36/69 GARS Asp256His 6.494 Paternally inherited
10 104476790 T T 14/30 SFXN2 Leu73Pro 4.906 Maternally inherited
7 100670236 C C 20/51 FIS1 Ala90Pro 3.824 Maternally inherited
11 47620527 A A 3/8 MTCH2 Tyr23His 3.680 Not confirmed in Sanger
sequencing
1 10286026 C G 22/46 KIF1B Ile732Met 3.092 Maternally inherited
Variants with PhyloP score > 2 are listed.
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and SLC25A4 have been reported in inherited PEO ped-
igrees with frequent comorbidity of mood disorders
[28]. Given the typical symptoms of major depressive
disorder in the present case, RRM2B should be added to
the list of genes causal for PEO associated with mood
disorders.
The identified P33S variant changes an amino acid resi-
due highly conserved among vertebrates. The amino-term-
inal region of p53R2, in which this altered amino acid is
located, is suggested to be crucial for interaction with p21
protein. p53R2 may contribute to DNA repair in coopera-
tion with p21 [29]. In its amino-terminal region, the
homozygous p.R41P variant was detected in a mitochon-
drial depletion syndrome case [21]. On the other hand,
other pathogenic missense variants have been located in
various sites of p53R2, including those involved in iron-
binding [18,20], those putatively crucial for homodimeriza-
tion of p53R2 [21,23] or heterotetramerization with the
RRM1 (ribonucleoside-diphosphate reductase large subu-
nit) homodimer [18,22], and so on. The relationships
between clinical phenotypes and the properties of variants,
as well as their underlying mechanisms, should be the sub-
ject of further investigations.
Conclusions
In this study, we describe a homozygous missense var-
iant in RRM2B that is strongly suggested to cause
arPEO. We were not only able to identify the disease-
associated variant, but could also exclude other candi-
dates (that is, variants in known PEO-related genes such
as POLG1, other mitochondrial genes in nucleic DNA
and mtDNA) using data from single exome sequencing.
This result further demonstrates the efficiency and effec-
tiveness of exome sequencing to detect causative var-
iants of rare, inherited, and genetically heterogeneous
diseases.
Materials and methods
Clinical information of the patient
The detailed clinical history, family history and laboratory
data of the studied subject are described elsewhere [4].
Briefly, a 43-year-old man presented with hearing loss,
bilateral ptosis, external ophthalmoplegia and muscle
weakness. Examinations revealed the existence of pigmen-
tary degeneration of the retina and gonadal atrophy. The
initial symptom of progressive hearing loss began at age
16 years. Depressive mood, anxiety and hypochondriacal
complaints were observed in his clinical course. His par-
ents were first cousins, he had no siblings, and no other
member of his family has a known history of neurological
illness. In the muscle biopsy, marked variation of muscle
fiber size, ragged red fibers, COX-negative fibers and mul-
tiple mtDNA deletions were detected. According to his
clinical history, family history and laboratory data, arPEO
was suspected.
The present study conformed to the Declaration of
Helsinki, and was approved by the RIKEN Wako Institute
Ethics Committee I, as well as the ethics committees of
Kagoshima University Graduate School of Medical and
Dental Sciences and other participating institutes. Writ-
ten informed consent was obtained from every subject.
Exome sequencing and data analysis
T o t a lD N Aw a so b t a i n e df r o mp e r i p h e r a lb l o o do ft h e
patient using standard protocols. Total DNA (3 μg) was
sheared into approximately 300-bp fragments using a
Covaris sonicator (Covaris, Woburn, MA, USA). A
paired-end exome library for Illumina sequencing was
prepared using the SureSelect Human All Exon Kit (Agi-
lent) following the manufacturer’s instructions. Massively
parallel sequencing was performed using one lane of the
Genome Analyzer II (Illumina) at RIKEN Omics Science
Center by the Life Science Accelerator system. Base call-
ing was performed by the Illumina pipeline with default
parameters. Obtained reads were mapped against the
human reference genome (UCSC hg18/GRCh36) using
CLC Genomics Workbench v4.0.2 software (CLC Bio,
Aarhus, Denmark) with default parameters. Variant call-
ing was performed using the SNP and DIP detection
tools in CLC Genomics Workbench v4.0.2 with default
parameters. Analysis of ROH was performed using
PLINK software v1.0.7 [30]. The primary aim of this
0
0.5
1
1.5
2
2.5
ND1/RNaseP ratio
ND4/RNaseP ratio
Patient
Patient (rep)
Control-1
Control-2
Control-3
Control-4
Figure 2 Relative amounts of mtDNA in skeletal muscle tissues
from the patient and four control subjects. ND1/RNaseP and
ND4/RNaseP ratios calculated by real-time quantitative PCR were
used to evaluate mtDNA levels. The mtDNA level in the patient was
comparable to those of controls. Values are relative to the average
of all four controls.
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to narrow down the list of candidate variants without
overlooking the causative variant. Therefore, we used
relatively small (1, 000 kb) sliding windows for ROH seg-
ments, did not consider local blocks of linkage disequili-
brium in the Japanese population, and did not exclude
t h ed a t ao fv a r i a n t sw h o s ef r equency was not registered
in dbSNP; those variants might not be polymorphic in
the Japanese population and possibly contributed to
extend the length of ROH. Conservation information for
the variants among 44 vertebrate species (phyloP score)
was collected from the UCSC genome browser [31].
Sanger sequencing
Sanger sequencing of PCR amplicons was performed to
confirm the detected disease-associated variant using a
3730 × L DNA Analyser (Applied Biosystems, Foster City,
CA, USA). The primers used were: forward, 5’-AGGCA-
GACAGGCTCTCAAAC-3’; reverse, 5’-GGCAGAATTA-
GATGCCATTG-3’.
Real-time quantitative PCR
The amount of nuclear DNA and mtDNA in the skeletal
muscle of the patient and four age- and sex-matched con-
trols (all males aged 39 to 48 years) was evaluated by real-
time quantitative PCR analysis according to the previously
validated methods [32]. Briefly, copy numbers of RNaseP
(for nuclear DNA), ND1 and ND4 (for mtDNA) were eval-
u a t e du s i n gt h eT a q M a nm e t h o d( A p p l i e dB i o s y s t e m s ) .
Analysis of the patient’s tissue was performed in two inde-
pendent reactions, and each experiment was triplicated.
ND1/RNaseP and ND4/RNaseP ratios were calculated as 2
[Ct(RNaseP)-Ct(each gene)].
Data accessibility
The sequence data from this study have been submitted
to dbGaP [33] (study accession [phs000392.v1.p1]).
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